Diverse monoclonal antibodies against the CA 19‐9 antigen show variation in binding specificity with consequences for clinical interpretation

The CA 19‐9 antigen is currently the best individual marker for the detection of pancreatic cancer. In order to optimize the CA 19‐9 assay and to develop approaches to further improve cancer detection, it is important to understand the specificity differences between CA 19‐9 antibodies and the consequential affect on biomarker performance. Antibody arrays enabled multiplexed comparisons between five different CA 19‐9 antibodies used in the analysis of plasma samples from pancreatic cancer patients and controls. Major differences were observed between antibodies in their detection of particular patient samples. Glycan array analysis revealed that certain antibodies were highly specific for the canonical CA 19‐9 epitope, sialyl‐Lewis A, while others bound sialyl‐Lewis A in addition to a related structure called sialyl‐Lewis C and modification with Nue5Gc. In a much larger patient cohort, we confirmed the binding of sialyl‐Lewis C glycan by one of the antibodies and showed that the broader specificity led to the detection of an increased number of cancer patients without increasing detection of pancreatitis patient samples. This work demonstrates that variation between antibody specificity for cancer‐associated glycans can have significant implications for biomarker performance and highlights the value of characterizing and detecting the range of glycan structures that are elevated in cancer.

[1]  R. Molina,et al.  CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer , 2012, Tumor Biology.

[2]  P. Andrews,et al.  Identification of blood‐protein carriers of the CA 19‐9 antigen and characterization of prevalence in pancreatic diseases , 2011, Proteomics.

[3]  D. Chan,et al.  Aberrant glycosylation associated with enzymes as cancer biomarkers , 2011, Clinical Proteomics.

[4]  X. Chen,et al.  Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. , 2011, Cancer research.

[5]  David F. Smith,et al.  Shotgun Glycomics: A Microarray Strategy for Functional Glycomics , 2010, Nature Methods.

[6]  B. Haab,et al.  High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays. , 2011, Methods in molecular biology.

[7]  C. Sato,et al.  Extensive enrichment of N-glycolylneuraminic acid in extracellular sialoglycoproteins abundantly synthesized and secreted by human cancer cells. , 2010, Glycobiology.

[8]  Edward Suh,et al.  A motif-based analysis of glycan array data to determine the specificities of glycan-binding proteins. , 2010, Glycobiology.

[9]  U. Mansmann,et al.  Application of a Time-Varying Covariate Model to the Analysis of CA 19-9 as Serum Biomarker in Patients with Advanced Pancreatic Cancer , 2010, Clinical Cancer Research.

[10]  M. Farnell,et al.  Predictive and Prognostic Value of CA 19-9 in Resected Pancreatic Adenocarcinoma , 2009, Journal of Gastrointestinal Surgery.

[11]  M. Hollingsworth,et al.  The Prevalence and Nature of Glycan Alterations on Specific Proteins in Pancreatic Cancer Patients Revealed Using Antibody-Lectin Sandwich Arrays* , 2009, Molecular & Cellular Proteomics.

[12]  B. Haab,et al.  Microarrays in glycoproteomics research. , 2009, Clinics in laboratory medicine.

[13]  W. Scheithauer,et al.  CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. , 2008, The Lancet. Oncology.

[14]  R. Kuick,et al.  Low‐volume, high‐throughput sandwich immunoassays for profiling plasma proteins in mice: Identification of early‐stage systemic inflammation in a mouse model of intestinal cancer , 2007, Molecular oncology.

[15]  T. Roach,et al.  High-throughput carbohydrate microarray profiling of 27 antibodies demonstrates widespread specificity problems. , 2007, Glycobiology.

[16]  A. Siriwardena,et al.  Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. , 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  D. Simeone,et al.  N-linked glycosylation profiling of pancreatic cancer serum using capillary liquid phase separation coupled with mass spectrometric analysis. , 2007, Journal of proteome research.

[18]  W. Hancock,et al.  Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. , 2006, Clinical chemistry.

[19]  Chi-Huey Wong,et al.  Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Varki,et al.  Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  J. Alper.  Turning Sweet on Cancer , 2003, Science.

[22]  N. Willich,et al.  CA 19-9 in the therapy monitoring and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy. , 2003, Anticancer research.

[23]  J. Alper.  Glycobiology. Turning sweet on cancer. , 2003, Science.

[24]  D. Couper,et al.  Distribution of Lewis (FUT3) genotype and allele: frequencies in a biethnic United States population , 2002, Annals of Hematology.

[25]  Maureen E. Taylor,et al.  Glycan arrays for functional glycomics , 2002, Genome Biology.

[26]  Y. Malykh,et al.  N-Glycolylneuraminic acid in human tumours. , 2001, Biochimie.

[27]  J. Dennis,et al.  Glycoprotein glycosylation and cancer progression. , 1999, Biochimica et biophysica acta.

[28]  Carolyn R. Bertozzi,et al.  Essentials of Glycobiology , 1999 .

[29]  S. Hirohashi,et al.  Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. , 1998, Cancer research.

[30]  M. Costache,et al.  Significance of Individual Point Mutations, T202C and C314T, in the Human Lewis (FUT3) Gene for Expression of Lewis Antigens by the Human α(1,3/1,4)-Fucosyltransferase, Fuc-TIII* , 1997, The Journal of Biological Chemistry.

[31]  J. Furuse,et al.  CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.

[32]  T. Ørntoft,et al.  Influence of Lewis α1-3/4-L-Fucosyltransferase (FUT3) Gene Mutations on Enzyme Activity, Erythrocyte Phenotyping, and Circulating Tumor Marker Sialyl-Lewis a Levels* , 1996, The Journal of Biological Chemistry.

[33]  M. Heikinheimo,et al.  Tumor Markers CA 125 and CA 19–9 in Cord Blood and During Infancy: Developmental Changes and Use in Pediatric Germ Cell Tumors , 1995, Pediatric Research.

[34]  S. Kawa,et al.  Elevated serum levels of Dupan-2 in pancreatic cancer patients negative for Lewis blood group phenotype. , 1991, British Journal of Cancer.

[35]  M. Prat,et al.  Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. , 1990, Gastroenterology.

[36]  Henrik Clausen,et al.  Molecular genetic basis of the histo-blood group ABO system , 1990, Nature.

[37]  M. Tempero,et al.  Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. , 1988, Cancer research.

[38]  M. Tempero,et al.  Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. , 1987, Cancer research.

[39]  W. Schmiegel,et al.  Characterization of CA 19-9 bearing mucins as physiological exocrine pancreatic secretion products. , 1986, Cancer research.

[40]  H. Koprowski,et al.  Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. , 1983, Cancer research.